全文获取类型
收费全文 | 41392篇 |
免费 | 3137篇 |
国内免费 | 1208篇 |
专业分类
耳鼻咽喉 | 191篇 |
儿科学 | 974篇 |
妇产科学 | 517篇 |
基础医学 | 6387篇 |
口腔科学 | 865篇 |
临床医学 | 2865篇 |
内科学 | 6402篇 |
皮肤病学 | 708篇 |
神经病学 | 3505篇 |
特种医学 | 619篇 |
外国民族医学 | 5篇 |
外科学 | 3281篇 |
综合类 | 5565篇 |
现状与发展 | 5篇 |
预防医学 | 1959篇 |
眼科学 | 495篇 |
药学 | 6343篇 |
4篇 | |
中国医学 | 1973篇 |
肿瘤学 | 3074篇 |
出版年
2024年 | 91篇 |
2023年 | 792篇 |
2022年 | 1957篇 |
2021年 | 1822篇 |
2020年 | 1389篇 |
2019年 | 1546篇 |
2018年 | 1530篇 |
2017年 | 1421篇 |
2016年 | 1285篇 |
2015年 | 1360篇 |
2014年 | 2220篇 |
2013年 | 2448篇 |
2012年 | 2032篇 |
2011年 | 2468篇 |
2010年 | 1956篇 |
2009年 | 1990篇 |
2008年 | 1995篇 |
2007年 | 1771篇 |
2006年 | 1643篇 |
2005年 | 1535篇 |
2004年 | 1443篇 |
2003年 | 1253篇 |
2002年 | 1084篇 |
2001年 | 819篇 |
2000年 | 797篇 |
1999年 | 698篇 |
1998年 | 563篇 |
1997年 | 574篇 |
1996年 | 501篇 |
1995年 | 467篇 |
1994年 | 402篇 |
1993年 | 291篇 |
1992年 | 241篇 |
1991年 | 246篇 |
1990年 | 185篇 |
1989年 | 155篇 |
1988年 | 167篇 |
1987年 | 132篇 |
1986年 | 144篇 |
1985年 | 288篇 |
1984年 | 304篇 |
1983年 | 239篇 |
1982年 | 269篇 |
1981年 | 214篇 |
1980年 | 198篇 |
1979年 | 181篇 |
1978年 | 135篇 |
1977年 | 94篇 |
1976年 | 103篇 |
1975年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Y. BÖTTIGER P. DOSTERT M. STROLIN BENEDETTI M. BANI F. FIORENTINI M. CASATI I. POGGESTI C. ALM G. ALVAN & L. BERTILSSON 《British journal of clinical pharmacology》1996,42(6):707-711
1 Nicergoline, an ergot derivative previously used as a vasodilator, has gained a new indication in treating the symptoms of senile dementia.
2 Nicergoline is rapidly hydrolysed to an alcohol derivative, 1-methyl-10-α-methoxy-9,10-dihydrolysergol (MMDL), which is further N -demethylated to form 10-α-methoxy-9,10-dihydrolysergol (MDL). A few individuals display aberrant metabolism of this drug, as shown by their diminished capacity to form the MDL metabolite. The aim of this study was to determine whether defective nicergoline metabolism is associated with the debrisoquine and/or the S-mephenytoin hydroxylation polymorphisms.
3 After a single, oral 30 mg dose of nicergoline, the plasma concentrations of its two metabolites were studied in 15 subjects, divided into three groups with respect to their debrisoquine and S-mephenytoin hydroxylation phenotypes.
4 The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l−1 and AUC (0, t h) 144 nmol l−1 h, mean MDL C max 183 nmol l−1 and AUC 2627 nmol l−1 h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL C max 356 nmol l−1 and AUC 10512 nmol l−1 h, MDL concentrations below limit of quantitation).
5 We conclude that the formation of MDL from MMDL in the metabolism of nicergoline is catalysed to a major extent by CYP2D6 and that the observed interindividual variation in the metabolic pattern of the drug is related to the debrisoquine hydroxylation polymorphism. 相似文献
2 Nicergoline is rapidly hydrolysed to an alcohol derivative, 1-methyl-10-α-methoxy-9,10-dihydrolysergol (MMDL), which is further N -demethylated to form 10-α-methoxy-9,10-dihydrolysergol (MDL). A few individuals display aberrant metabolism of this drug, as shown by their diminished capacity to form the MDL metabolite. The aim of this study was to determine whether defective nicergoline metabolism is associated with the debrisoquine and/or the S-mephenytoin hydroxylation polymorphisms.
3 After a single, oral 30 mg dose of nicergoline, the plasma concentrations of its two metabolites were studied in 15 subjects, divided into three groups with respect to their debrisoquine and S-mephenytoin hydroxylation phenotypes.
4 The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL C
5 We conclude that the formation of MDL from MMDL in the metabolism of nicergoline is catalysed to a major extent by CYP2D6 and that the observed interindividual variation in the metabolic pattern of the drug is related to the debrisoquine hydroxylation polymorphism. 相似文献
102.
本文报告了2,4,6-三硝基甲苯(TNT)的代谢物,2-氨基-4,6-二硝基甲苯2和2,4-二氨基-6-硝基甲苯3的合成。以邻甲基苯甲酸为原料,经硝化(HNO_3-H_2SO_4)和Schmidt反应(NaN_3-H_2SO_4)得到2,用NaHS还原TNT的方法合成化合物3。 相似文献
103.
Low doses of the uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (MK-801) induce locomotor stimulation in mice, whereas higher doses are associated with ataxia, stereotyped behaviors and catalepsy. We investigated the role of dopamine receptors and presynaptic dopamine neurons in the locomotor effects of dizocilpine. For comparison, we studied several other drugs that induce locomotor stimulation in mice. Pretreatment of male mice with haloperidol (0.1 mg/kg, i.p.) completely prevented the stimulation of normally coordinated locomotion induced by a non-intoxicating dose of dizocilpine (0.1 mg/kg, i.p.); haloperidol also attenuated the locomotor stimulation produced by phencyclidine (PCP, 1 and 2 mg/kg, i.p.), d-amphetamine (2 and 5 mg/kg, i.p.) and diazepam (0.5 mg/kg, i.p.). Haloperidol (doses up to 2.5 mg/kg) did not attenuate the ataxia and decreased locomotion induced by higher doses of dizocilpine (1 and 2 mg/kg). The active cis isomer of flupenthixol (0.5 mg/kg, i.p.), an antagonist of both D1 and D2 dopamine receptors, also diminished the stimulant actions of all of the test drugs, whereas its inactive trans form did not. The selective D1 antagonist R(±)-SCH 23390 (0.1 mg/kg) and the selective D2 antagonist raclopride (1 mg/kg) had little effect on the stimulatory effect of dizocilpine, although they did reduce the stimulation produced by PCP, d-amphetamine and diazepam. However, pretreatment with a combination of R(±)-SCH 23390 and raclopride completely prevented dizocilpine-induced locomotor stimulation. Pretreatment with α-methyl-p-tyrosine (AMPT, 50 and 250 mg/kg), an inhibitor of tyrosine hydroxylase, or with 6-hydroxydopamine (6-OH-DA, 50 μg, i.c.v.), a neurotoxin that destroys brain dopaminergic and noradrenergic neurons, did not attenuate the locomotor stimulation induced by dizocilpine, although these treatments did reduce the stimulant effects of d-amphetamine. In AMPT or 6-OH-DA pretreated mice, haloperidol (0.125 mg/kg) prevented the stimulatory effect of dizocilpine. These results support a role for dopamine receptors in the stimulation of normally coordinated locomotion by dizocilpine. However, the locomotor stimulant effect of dizocilpine, unlike that of d-amphetamine, can be expressed in the presence of D1 or D2 dopamine receptor blockade and does not appear to be dependent on intact presynaptic mechanisms. 相似文献
104.
Contralateral intrastriatal injection of 0.1 pmol or 1 pmol of endothelin-1 produced ipsilateral turning behaviour in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the nigrostriatal pathway. This effect could be abolished by pretreatment with either the endothelinETA/B receptor antagonist bosentan (1 nmol, intrastriatally) or the dopamine D2 receptor antagonist raclopride (0.1 mg/kg, s.c.) suggesting that endothelin is acting at endothelin receptors to evoke ipsilateral turning behaviour and that this response is mediated by dopamine. Similar ipsilateral turning behaviour was observed upon intrastriatal injection of 1 pmol of endothelin-3 or the specific ETB receptor agonist, [Ala1,3,11,15]endothelin-1 when compared to endothelin-1. Pretreatment with the specific ETB receptor antagonist BQ788 blocked the ipsilateral turning response to intrastriatal injection of endothelin-1 while pretreatment with the specific ETA receptor antagonist BQ123 did not significantly change the response to injection of endothelin-1. This indicates that endothelin-1, which has affinity for both ETA and ETB receptors, is most likely acting at the ETB receptor to elicit its effect. These results suggest that low doses of endothelin may act at ETB receptors to evoke the release of dopamine from the striatum in vivo. 相似文献
105.
The greater potency of morphine-6-glucuronide (M6G) as well as the inactivity of morphine-3-glucuronide (M3G) with respect to the antinociceptive effects of the parent molecule, morphine (MOR), have been well established. It has been suggested that M3G is an antagonist of MOR's antinociceptive and respiratory depressive effects. The present study addressed the central nervous system (CNS) interaction of these opiate metabolites on their metabolic and hormonal effects. Whole body glucose kinetics were assessed on conscious, chronically catheterized, unrestrained rats. M3G (5 μg) or H2O (5 μl) was injected intracerebroventricularly (i.c.v.) 15 min prior to the bolus administration of H2O (5 μl), M6G (1 μg), or MOR (80 μg). i.c.v. M3G (5 μg) resulted in behavioral excitation, hyperglycemia (+50%), stimulation of glucose rate of appearance (Ra; +100%), glucose rate of disappeaance (Rd; +70%), and metabolic clearance rate (MCR; +33%) within 30 min after injection with no alterations in hormone concentrations. i.c.v. M6G and MOR produced progressive hyperglycemia with significantly high catecholamine and corticosterone levels. M3G pretreatment resulted in enhanced elevations in plasma glucose levels (+52% and +18%), plasma lactate (+138% and +108%), norepinephrine (+96% and +30%), and epinephrine (+62% and +67%) in response to both i.c.v. MOR and M6G administration. These findings suggest a non-opiate and non-hormonal mechanism for M3G-induced hyperglycemia. In contrast, the metabolic and hormonal responses to i.c.v. M6G and MOR are associated with elevations in catecholamine and corticosterone levels, which are remarkably enhanced by M3G pretreatment, most likely through accelerated catecholamine release. Our findings suggest a modulatory role for MOR glucuronidation, not only by rendering it inactive, as in the case of M3G, but by an interplay of the metabolic effects of the parent molecule and its metabolite 相似文献
106.
本文报道给C57小鼠腹腔注射不同剂量1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)后,发现组3(MPTP35 mg/kg,每天一次,共7天)鼠肝匀浆、线粒体和微粒体的膜丙二醛含量明显增加,与对照组相比分别增加70.5%,67%和51.4%(P<0.01),而组1(MPTP 35mg/kg,每4小时一次,共3次)和组2(MPTP35mg/kg,每天一次,共4天)鼠肝丙二醛含量与对照组相近。结果表明MPTP有明显地促进鼠肝脂质过氧化的作用,并与其剂量有关。 相似文献
107.
Buprenorphine, a partial mu-opioid receptor agonist, has been proposed as a treatment for cocaine abuse. However, studies
in animals have produced conflicting results on the nature of the interaction between buprenorphine and cocaine. In some studies,
buprenorphine attenuated the effects of cocaine and in others it enhanced them. The purpose of the present study was to evaluate
the interaction of buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat. Both buprenorphine (0.003–0.1
mg/kg) and cocaine (1.0– 30 mg/kg) alone produced dose-dependent increases in rotational behavior. Buprenorphine produced
long-lasting turning with a peak at 60 min after administration, while cocaine produced turning that peaked immediately after
administration and lasted for about 2 h. To distinguish simple additivity from other possible outcomes, we determined the
relative potency of each drug alone, using a defined level of effect: 150 turns above the saline control in 4 h. This effect
was produced by 10.0 mg/kg cocaine alone and by 0.0175 mg/kg buprenorphine alone. Based on these results, fixed ratio combinations
were tested and the experimentally derived effects were compared to the theoretically additive values, using an isobolographic
analysis. The fixed ratio combinations of the two drugs tested produced turning greater than predicted from simple additivity.
This finding provides statistically-supported evidence for synergism between the actions of buprenorphine and cocaine.
Received: 28 January 1997 / Final version: 7 June 1997 相似文献
108.
109.
Ryoji Tanei Tatsuo Yamamoto Hideki Yokono Tadashi Motoori 《The Journal of dermatology》1997,24(8):514-521
We report a case of an 81-year-old woman in whom lichenoid eruptions and Sjögren-like sicca syndrome developed 45 days after cholecystectomy. During surgery, one unit (130 ml) of unirradiated packed red blood cells from a male donor was transfused. The lichenoid eruptions cleared up with exfoliation; however, sicca symptoms remained during the follow-up period of four years. Histological examinations of both skin and lip biopsy specimens were in agreement with those of graft-versus-host disease (GVHD). A Y-chromosomal body was identified in the lymphocytes in the skin lesion by staining with quinacrine dihydrochloride and in the lip lesion by a method with in situ hybridization. The findings suggest that this case demonstrated the manifestations of non-fatal transfusion-associated GVHD. 相似文献
110.
R. Gottschalk C. Seidl T. Löffler E. Seifried D. Hoelzer J.P. Kaltwasser 《Tissue antigens》1998,51(3):270-275
Abstract: Genetic hemochromatosis (GH) is closely associated with genes of the major histocompatibility complex (MHC) on chromosome 6. Recently, a candidate gene for GH, with structural similarities to MHC class I genes, designated HLA-H and presently named HFE, has been cloned. The HFE gene is localized telomeric to the MHC and several reports have indicated that the HFE gene is mutated in GH patients. In the present study we have analyzed the relationship of HFE gene variants and disease manifestation in GH patients and family members. Fifty-seven patients with GH, 73 family members and 153 healthy blood donors were studied for the amino acid dimorphism at codon 63 (His63Asp=H63D) and codon 282 (Cys282Tyr= C282Y) of the HFE gene. The codon 63 and 282 dimorphism were defined by PCR amplification of genomic DNA samples and restriction enzyme digestion using RsaI/SnaBI for C282Y and Bcll/Mbo 1 for H63D. Ferritin, transferrin serum levels and total iron-binding capacity were determined prior to therapeutic intervention. The Tyr-282 substitution occurred in 53 (93%) of patients compared with 8 (5.2%) of controls (OR=169, P >0.0001). Fifty-one (90%) patients were Tyr-282 homozygous. In contrast, the Asp-63 substitution was present in 5 (8.8%) of the patients compared with 34 (22%) of controls (OR=0.39, P =NS) with none of the patients being homozygous. In Tyr-282 homozygous GH patients serum ferritin levels, transferrin saturation, liver iron and liver iron index were elevated significantly compared to Tyr-282-negative patients, whereas no difference was observed between Tyr/Cys-282 heterozygous and Tyr-282-negative patients. 相似文献